Societal CDMO, Inc.

Good day, ladies and gentlemen, and welcome to the Societal CDMO First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will go into the question and answer session, and instructions will follow at that time. As a reminder, this conference call may be recorded. I would now like to hand the conference over to Stephanie Diaz of Societal's Investor Relations Group. Please go ahead.

Thank you. Hello, and thank you for joining us. On today's call, we have David Enloe, President and CEO, and Ryan Legge, Chief Financial Officer. Today we will be providing an overview of Societal's contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended March 31, 2023. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, May 10, 2023, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the current beliefs of the company, which involve a number of assumptions, risks, and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at societalcdmo.com. With that, I will turn the call over to David Enloe, Societal's President and CEO.

Thank you, Stephanie, and thank you to everyone participating today via webcast. As reported during our March webcast, 2022 was a transformative year for Societal, And we have been pleased to ride the momentum created into the first quarter of 2023, despite the overall headwinds our industry is experiencing. Since the beginning of 2023, we have announced multiple new business wins, including new customer wins, as well as the expansion of work with multiple existing clients. During the period, we were also very pleased to announce the FDA's approval of Societal's first commercially manufactured tablet product, an important expansion of our capabilities that extends beyond the company's longstanding expertise in commercial capsule production. I will provide a more detailed review of our Q1 2023 achievements following an overview of our financial results for the quarter ended March 31, 2023. For that, I'll turn the call over to Ryan.